Seeking Funding For Cancer Vaccine Clinical Trial And Fast Track Commercialization

BIOVEN, a biotechnology company specializing in therapeutic vaccines for cancer, is targeting to raise US$16million to fund its clinical trials and fast track the commercialization of its three breakthrough therapeutic cancer vaccine products and a therapeutic hepatitis B vaccine. The company secured ownership and rights to market the Cuban technology globally for US$32 million. “We are looking for investors to come into the project,” said Chairman Mukhriz Mahathir.

More: continued here

Filed under: Cancer on January 9th, 2008